Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,583.16
    -1,431.08 (-2.86%)
     

  • CMC Crypto 200

    1,256.60
    -101.41 (-7.47%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Indivior files patent lawsuits against generic Suboxone rivals

Reuters - UK Focus

Sept 15 (Reuters) - Indivior (Frankfurt: 2IVA.F - news) said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's revenue.

The lawsuits were filed against Dr. Reddy's, Allergan Plc (Frankfurt: A1W5NE - news) 's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.

The lawsuits allege that these companies have infringed a patent that relates to an oral film containing buprenorphine and naloxone, the London-listed drugmaker said in a statement.

Indivior has already been involved in patent infringement litigations with the same companies over other patents related to the Suboxone film. (Reporting by Justin George Varghese in Bengaluru; editing by David Clarke)